Tumor Cell Death Drives Tumor-Promoting IL-6⁺ iCAF formation via P2X7-activation

Read full text Summarise with VIRAT
Authors: Ciarán Osmond McDonnell, Valeriya V. Zinina, Amina Othman, Larissa Launhardt, Anna I. Brichkina, Fatma Aktuna, Magdalena Brkic, Matthias Lauth, Eliana Stanganello, Mark R. Schmitt
Cited by: 0
References: 36

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Abstract Chemotherapy resistance in pancreatic ductal adenocarcinoma is commonly attributed to tumor cell–intrinsic mechanisms, yet how cytotoxic therapy reshapes the tumor microenvironment remains incompletely understood. Here we show that PDAC cells exposed to cytotoxic agents reprogram pancreatic stellate cells toward an inflammatory cancer-associated fibroblast phenotype. Mechanistically, chemotherapy triggers the release of ATP from dying PDAC cells, which activates P2X7 signaling in PSCs in a paracrine manner, leading ERK activation and inflammatory polarization. In turn, therapy-educated PSCs promote tumor cell proliferation, induce resistance-associated transcriptional programs and impair CD8⁺ T cell–mediated cytotoxicity in an IL-6–dependent manner. Pharmacological inhibition of P2X7 suppressed stromal IL-6 induction and enhanced gemcitabine efficacy in vivo. These findings identify a therapy-induced ATP–P2X7–IL-6 axis that links tumor cell death to stromal reprogramming and adaptive resistance in PDAC.

Fields of Study & Subjects

Pancreatic and Hepatic Oncology Research Adenosine and Purinergic Signaling Pancreatitis Pathology and Treatment

Publication details

Journal / source
bioRxiv (Cold Spring Harbor Laboratory)
Publication date
20 March 2026
Language
EN
Document type
Preprint